TY - JOUR
T1 - Factors predicting survival in peripheral T-cell lymphoma in the USA
T2 - A population-based analysis of 8802 patients in the modern era
AU - Petrich, Adam M.
AU - Helenowski, Irene B.
AU - Bryan, Locke J.
AU - Rozell, Shaina A.
AU - Galamaga, Robert
AU - Nabhan, Chadi
N1 - Publisher Copyright:
© 2014 John Wiley & Sons Ltd.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.
AB - Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.
KW - Histopathology
KW - Prognostic factors
KW - Radiotherapy
KW - T-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84922779526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922779526&partnerID=8YFLogxK
U2 - 10.1111/bjh.13202
DO - 10.1111/bjh.13202
M3 - Article
C2 - 25382108
AN - SCOPUS:84922779526
SN - 0007-1048
VL - 168
SP - 708
EP - 718
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -